Cellseed Inc. · TSE:7776
Cellseed — FY2020 Earnings Presentation
27 slides from Cellseed's earnings presentation, Feb 19, 2021
Slide 1: Fiscal 2020 Earnings Results Presentation
CellSeed Inc. Fiscal 2020 Earnings Results Presentation JASDAQ Growth Stock Code:7776
Slide 2: Contents
Contents Company Profile Financial summary FY 12/2020 Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023 Copyright © CellSeed Inc. All Rights Reserved. 1
Slide 3: CellSeed Inc. Corporate Information
CellSeed Inc. Corporate Information Established May, 2001 Core competence Cell Sheet Engineering based on Temperature Responsive Polymers Listed JASDAQ（7776) in 2010 Business Regenerative Medical Regenerative Medicine Products Business Supporting Business • Commercialization of Cell Sheet Therapies
Slide 4: Cell Sheet Engineering
“Cell Sheet Engineering” Platform Technology of Regenerative Medicine 37℃ Hydrophobic ⇔ 20℃ Hydrophilic Copyright © CellSeed Inc. All Rights Reserved. 3
Slide 5: Our Business Model
Our Business Model Mission We take the initiative of contributing to global health care in the valuable and innovative field of regenerative medicine. Medical Hospitals Seeds Products Patients Treatment University Base of Innovation Collaborative Fee Medical Research Expenses Business Alliance Partn
Slide 6: Development of Treatment Using Cell Sheet Engineering
Development of Treatment Using Cell Sheet Engineering Copyright © CellSeed Inc. All Rights Reserved. 5
Slide 7: Expansion of Cell Sheet Engineering
Expansion of Cell Sheet Engineering 120 CSTEC 総出願件数 Patents 100 Papers ⽂献数 80 60 40 20 0 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Establishment of Overseas sales for CellSeed Inc Upcell🄬 launched…
Slide 8: Contents
Contents Company Profile Financial summary FY 12/2020 Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023 Copyright © CellSeed Inc. All Rights Reserved. 7
Slide 9: Financial summary FY 12/2020
Financial summary FY 12/2020 FY2019 Consolidated FY2020 Consolidated （January 2019 – （January 2020 - December 2020） December 2019） Change from Amount Change Amount Previous Period （Millions of Yen） （Millions of Yen） （Millions of Yen） （%） Net sales 199 -76 -27.7 275 Operating profit -719 61 － -780 Or
Slide 10: Epithelial Cell Sheet for Esophageal Regeneration
Epithelial Cell Sheet for Esophageal Regeneration (CLS2702C/D) A medical treatment developed by Tokyo Women’s Medical University as a regenerative treatment for esophageal cancer (to heal esophageal wound and prevent stricture) Cell sheet is on a temperature-responsive cell culture ware and then
Slide 11: Clinical Research and Clinical Trials of Esophageal Cell Sheet
Clinical Research and Clinical Trials of Esophageal Cell Sheet Tokyo Women’s Medical University Clinical Research at Universities 2008－2014＜Japan＞ Tokyo Womenʼs Medical Univ. 10case Tokyo Womenʼs Medical Univ. Basic 10case Development and Nagasaki Univ. Agreement ＜Europe＞ Karolinska University Hos
Slide 12: Epithelial Cell Sheet Regenerative Medicine Business in FY Ended December 2020
Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2020 Epithelial Cell Sheet for Esophageal Regeneration Clinical trials conducted for obtaining approval April 2016 Clinical trials started March 2019 Clinical trials completed October 2020 Additional clinical trial plan
Slide 13: Chondrocyte Sheet
Chondrocyte Sheet Disease characteristics • Causes︓ageing・obesity traumatic • No treatment to regenerate lost cartilage is available In Japan, estimated number of potential patients about 30 million persons of which, about 10 million shows symptoms. Go Omori, Yoshio Koga and others From epidemio
Slide 14: Overview of Chondrocyte Sheet Project
Overview of Chondrocyte Sheet Project Clinical Research at University Tokai University School of Medicine Prof. Masato Sato, School of Medicine, Tokai University Started medial treatment in ＜Autologous Cartilage Sheets＞ • 2010 Clinical study started, 8 cases Tokai University completed as Advanced
Slide 15: Autologous chondrocyte sheets
Autologous chondrocyte sheets Started medial treatment in Tokai University as Advanced Medicine B Collect Autologous Manufacture Cell Transplant to Patient Cartilage Cells Sheet chondrocyte sheets Indications︓Knee Osteoarthritis Copyright © CellSeed Inc. All Rights Reserved. 14
Slide 16: Allogeneic chondrocyte sheets
Allogeneic chondrocyte sheets Preparation of Cell Stock Master Working Cell Cell Bank Bank Cell Suspension Culture Evaluation test Quality/Safety In liq.Nitrogen In liq.Nitrogen Transport- ation Polydactyly donors Collection of tissue Manufacture Packaging Lot release test Thawing Culture CellSheet
Slide 17: Cartilage Cell Sheet Regenerative Medicine Business in FY Ended December 2020
Cell Sheet Regenerative Medicine Business in the Fiscal Year Ended December 2020 Cartilage Cell Sheets Autologous Cartilage Cell Sheets August 2020 Contracted manufacturing of autologous cartilage sheets for Advanced Medicine B December 2020 Debriefing session on the results of autologous ca
Slide 18: CellSeed Temperature Sensitive Cell Cultureware Lineup
CellSeed Temperature Sensitive Cell Cultureware Lineup UpCell® RepCell ® HydroCell ® Cell Sheet Recovery Cell Recovery Ultra-Low Adhesion Cell （Temperature Sensitive） （Temperature Sensitive） Cultureware Temperature-responsive Temperature-responsive Low cell binding cell cultureware for "Cell c
Slide 19: Regenerative Medicine Supporting Business
Regenerative Medicine Supporting Business 1. Regenerative Cell Sheet Product Manufacture Method 2. Facility Management, 3. Cell Culturing Technician Development, Consigned Application Submission Support Training Manufacture Consigned manufacture Support for certification Cell sheet culturing t
Slide 20: Regenerative Medicine Supporting Business in FY Ended December 2020
Regenerative Medicine Supporting Business in the Fiscal Year Ended December 2020 Sales Activities for Equipment Initiated the supply of products to new markets to facilitate the mass 国内売上 Domestic sales cultivation of cells for research in order to develop treatments or 海外売上 Overseas sales preve
Slide 21: Debriefing session on autologous cartilage cell sheet treatment at Taiwan
A debriefing session on the results of autologous cartilage cell sheet treatment at Taiwan A debriefing session on the results of autologous cartilage cell sheet treatment was held at Healthcare Expo Taiwan at Taiwan on December 5th, 2020, organized by MetaTech Inc. and E- DA Hospital, E-DA Healthca
Slide 22: The 2nd Cell Sheet Engineering Innovation Forum
The 2nd Cell Sheet Engineering Innovation Forum The Second Cell Sheet Engineering and Innovation Forum, which had to be postponed from autumn last year due to the spread of the novel coronavirus, will be held in November 2021. • Date Monday, November 1, 2021 • Speakers Tatsuya Shimizu, Ph,D., M.D. P
Slide 23: Contents
Contents Company Profile Financial summary FY 12/2020 Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023 Copyright © CellSeed Inc. All Rights Reserved. 22
Slide 24: Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023
Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023 Cell Sheet Regenerative Medicine Business 1 Began additional clinical trials for 2 Accelerated the acquisition of non-clinical data in order to epithelial cell sheet for esophageal submit the clinical trial plan regeneration, aiming to ap
Slide 25: Regarding Overseas Businesses
Mid-term Business Plan Fiscal Year 2021 to Fiscal Year 2023 Regarding Overseas Businesses 5 6 Reconstructing the Proactively promoting collaboration with MetaTech business partnerships for the Inc. and Taiwanese joint global expansion of Japanese ventures for the acquisition of cell sheet engineer
Slide 26: Mid-term Business Plan Financial Targets
Mid-term Business Plan (2021 – 2023) Financial Targets (Unit: Million yen; Presented with fractions less than one million yen rounded off) Profit Operating Ordinary attributable Net Sales Profit Profit to owners of parent FY2021（Estimate） 213 -976 -998 -998 FY2022（Target） 1,400 20 19 10 FY2023（Targe
Slide 27: This presentation is made by CellSeed Inc. solely for the disclosure of the financial
This presentation is made by CellSeed Inc. solely for the disclosure of the financial statements, and not published for the purpose of soliciting sales or purchases of securities in Japan and any other regions. Copyright © CellSeed Inc. All Rights Reserved.